Business Description
Compare
Compare
Traded in other countries / regions
02105.Hong Kong4U4.Germany IPO Date
2023-06-29Description
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.82 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.32 | |||||
| 9-Day RSI | 60.19 | |||||
| 14-Day RSI | 55.45 | |||||
| 6-1 Month Momentum % | -77.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.58 | |||||
| Quick Ratio | 6.58 | |||||
| Cash Ratio | 6.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -31.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -85.3 | |||||
| ROIC % | -164.35 | |||||
| ROC (Joel Greenblatt) % | -4751.2 | |||||
| ROCE % | -97.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.33 | |||||
| Price-to-Tangible-Book | 3.92 | |||||
| EV-to-EBIT | -2.35 | |||||
| EV-to-EBITDA | -2.35 | |||||
| EV-to-FCF | -5.05 | |||||
| Price-to-Net-Current-Asset-Value | 4.05 | |||||
| Price-to-Net-Cash | 4.12 | |||||
| Earnings Yield (Greenblatt) % | -42.55 | |||||
| FCF Yield % | -12.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Laekna Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | |||
| EPS (TTM) (HK$) | -3.303 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 55.45 | ||
| 14-Day ATR (HK$) | 0.745856 | ||
| 20-Day SMA (HK$) | 6.182 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (HK$) | 3.15 - 26.45 | ||
| Shares Outstanding (Mil) | 390.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Laekna Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Laekna Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Laekna Inc Frequently Asked Questions
What is Laekna Inc(HKSE:02105)'s stock price today?
The current price of HKSE:02105 is HK$7.49. The 52 week high of HKSE:02105 is HK$26.45 and 52 week low is HK$3.15.
When is next earnings date of Laekna Inc(HKSE:02105)?
The next earnings date of Laekna Inc(HKSE:02105) is .
Does Laekna Inc(HKSE:02105) pay dividends? If so, how much?
Laekna Inc(HKSE:02105) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers